Lipideon Biotechnology

Lipideon Biotechnology AG is a drug R&D company, focusing on the treatment of arteriosclerosis and related cardiovascular diseases.

Lipideon Biotechnology AG is a Swiss stock company founded in Zurich as an ETH spin-off by Dr. Helmut Hauser in 2002. They are a drug R&D company, focusing on the treatment of arteriosclerosis and related cardiovascular diseases. Their strategy is to develop a new class of non-absorbable drugs that inhibit cholesterol absorption in the small intestine and as a result reduce serum cholesterol levels. This carries the potential for safer and improved treatment of dyslipidemia, the main underlying cause of artherosclerosis that eventually leads to stroke and heart attacks. Arteriosclerosis is a major health problem in Western industrialized nations affecting more than 50% of the total population and an increasing number of people in the rest of the world. Cholesterol-lowering drugs have reached worldwide sales of $ 34.7 billion in 2007.